Transfusion medicine handbook

[1]

European Medicines Agency, "Hydroxyethyl starch solutions: CMDh introduces new measures to protect patients," 17 July 2018. [Online]. Available: https://www.ema.europa.eu/en/documents/referral/hydroxyethyl-starch-article-107i-referral-hydroxyethyl-starch-solutions-cmdh-introduces-new-measures_en-0.pdf. [Accessed 08 March 2023].

[2]

Medsafe, "New Zealand Data Sheet- VOLUVEN 6%," September 2021. [Online]. Available: https://medsafe.govt.nz/profs/Datasheet/v/Voluveninf.pdf. [Accessed 07 March 2023].

[3]

Medsafe, "New Zealand Data Sheet- Volulyte 6%," September 2021. [Online]. Available: https://medsafe.govt.nz/profs/Datasheet/v/volulytesol.pdf. [Accessed 07 March 2023].

[4]

Medsafe, "New Zealand Data Sheet- Binocrit," 02 November 2021. [Online]. Available: https://medsafe.govt.nz/profs/datasheet/b/binocritinj.pdf. [Accessed 07 March 2023].

[5]

Medsafe, "New Zealand Data Sheet- EPREX," 20 January 2022. [Online]. Available: https://www.medsafe.govt.nz/profs/Datasheet/e/eprexinj.pdf. [Accessed 07 March 2023].

[6]

Medsafe, "New Zealand Data Sheet- NeoRecormon," 19 May 2020. [Online]. Available: https://medsafe.govt.nz/profs/datasheet/n/Neorecormoninj.pdf. [Accessed 04 November 2021].

[7]

Medsafe, "New Zealand Data Sheet- Revolade," 30 October 2020. [Online]. Available: https://www.medsafe.govt.nz/profs/Datasheet/r/revoladetab.pdf. [Accessed 04 November 2021].

[8]

PHARMAC, "9 February 2021: OIA response | Annual usage of recombinant factor VIII," 09 February 2021. [Online]. Available: https://pharmac.govt.nz/about/what-we-do/accountability-information/official-information-act/2021-oia-responses/9-february-2021-oia-response-annual-usage-of-recombinant-factor-viii/. [Accessed 04 November 2021].

[9]

Medsafe, "New Zealand Data Sheet- Novoseven RT," 06 November 2018. [Online]. Available: https://medsafe.govt.nz/profs/datasheet/n/NovoSevenRTinj.pdf. [Accessed 05 November 2021].

[10]

Medsafe, "New Zealand Data Sheet- Minirin," November 2017. [Online]. Available: https://medsafe.govt.nz/profs/Datasheet/m/minirininj.pdf. [Accessed 10 November 2021].

[11]

Medsafe, "New Zealand Data Sheet- Octostim," November 2017. [Online]. Available: https://medsafe.govt.nz/profs/datasheet/o/Octostiminj.pdf. [Accessed 10 November 2021].

[12]

Medsafe, "New Zealand Data Sheet- Cyklokapron," 20 April 2021. [Online]. Available: https://medsafe.govt.nz/profs/datasheet/c/Cyklokaprontabinj.pdf. [Accessed 10 November 2021].

[13]

National Blood Authority (Australia), "Preoperative anaemia identification, assessment and management.," June 2014. [Online]. Available: https://www.blood.gov.au/system/files/documents/preoperative-anaemia-identification-assessment-and-management-case-study%20grey%20cover%20v4.pdf. [Accessed 17 November 2021].

[14]

Medsafe, "New Zealand Data Sheet- Desmopressin PH&T Nasal Spray Solution," February 2021. [Online]. Available: https://medsafe.govt.nz/profs/Datasheet/d/DesmopressinPHTnasalspray.pdf. [Accessed 10 November 2021].

[15]

R. Matthews and A. Young, "Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomized, placebo-controlled trial," Journal of Emergency Medicine, vol. 58, no. 1, pp. 171-172, 2020.

[16]

I. Roberts, H. Shakur, A. Afolabi, K. Brohi, T. Coats, Y. Dewan, S. Gando, G. Guyatt, B. J. Hunt, C. Morales, P. Perel, D. Prieto-Merino and T. Woolley, "The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.," The Lancet, vol. 377, no. 9771, pp. 1096-1101, 2011.

[17]

J. A. Williams-Johnson, A. H. McDonald, G. G. Strachan and E. W. Williams, "Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial," The Lancet, vol. 376, no. 9734, pp. 23-32, 2010.